FDA Clears AI Software for Lumbar Spine MRI Analysis
The MSKai software provides AI-powered segmentation, labeling, and measurement tools for assessment of T2-weighted MRIs of the lumbar spine.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MSKai software, which offers a variety of adjunctive artificial intelligence (AI) tools for evaluating lumbar spine magnetic resonance imaging (MRI).
Through assessment of T2-weighted MRI scans of the lumbar spine, the MSKai software provides pathology detection, anatomical segmentation, labeling, and measurements within seconds, according to MSKai, the developer of the software.
For adjunctive assessment of lumbar spine MRIs, the newly FDA-cleared MSKai software provides AI-powered pathology detection, anatomical segmentation and measurements within seconds, according to MSKai, the developer of the software. (Image courtesy of Adobe Stock.)
The company maintained that the MSKai software can facilitate pre-surgical authorizations as well as monitoring of post-intervention treatments.
"The FDA's decision confirms that MSKai meets rigorous safety and performance standards as a spine imaging tool," said Chip Wade, Ph.D., chief operating officer at MSKai. "We're proud to deliver a product that gives healthcare professionals enhanced capabilities in lumbar spine analysis while reinforcing the central role of expert clinical judgement."
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
